Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMIGD3 | P0DMS9 | 5/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | SELE | P16581 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11480471 | 0.79 | ALDH1A1 (0.71) | TMIGD3ADORA1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL29990964 | 0.79 | KDM4E (0.43) | TMIGD3ADORA1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL13343603 | 0.78 | TMIGD3 (0.61) | TMIGD3ADORA1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL8189842 | 0.77 | TMIGD3 (0.60) | TMIGD3ADORA1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL29003800 | 0.76 | ALDH1A1 (0.38) | TMIGD3ADORA1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL1970640 | 0.75 | ALDH1A1 (0.61) | TMIGD3ADORA1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL1969459 | 0.74 | ALDH1A1 (0.56) | TMIGD3ADORA1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL1973000 | 0.74 | ALDH1A1 (0.56) | TMIGD3ADORA1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL7058912 | 0.74 | SMN1; SMN2 (0.74) | TMIGD3ADORA1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL8200644 | 0.74 | ALDH1A1 (0.57) | TMIGD3ADORA1ALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102149718-A | Fused heterocyclic compound | LG LIFE SCIENCES LTD (KR) | 2011-08-10 | — | — | CN | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | TMIGD3 2869/4885ADORA1 715/4885ALDH1A1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.